Arcutis Biotherapeutics (ARQT) EBIAT (2021 - 2025)
Historic EBIAT for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $7.4 million.
- Arcutis Biotherapeutics' EBIAT rose 11783.95% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.3 million, marking a year-over-year increase of 7733.19%. This contributed to the annual value of -$140.0 million for FY2024, which is 4657.85% up from last year.
- Latest data reveals that Arcutis Biotherapeutics reported EBIAT of $7.4 million as of Q3 2025, which was up 11783.95% from -$15.9 million recorded in Q2 2025.
- Arcutis Biotherapeutics' 5-year EBIAT high stood at $7.4 million for Q3 2025, and its period low was -$107.7 million during Q3 2022.
- Over the past 5 years, Arcutis Biotherapeutics' median EBIAT value was -$52.3 million (recorded in 2024), while the average stood at -$50.2 million.
- Per our database at Business Quant, Arcutis Biotherapeutics' EBIAT crashed by 8902.95% in 2022 and then skyrocketed by 11783.95% in 2025.
- Arcutis Biotherapeutics' EBIAT (Quarter) stood at -$71.3 million in 2021, then dropped by 0.97% to -$72.0 million in 2022, then rose by 7.96% to -$66.3 million in 2023, then surged by 83.72% to -$10.8 million in 2024, then skyrocketed by 168.69% to $7.4 million in 2025.
- Its EBIAT was $7.4 million in Q3 2025, compared to -$15.9 million in Q2 2025 and -$25.1 million in Q1 2025.